Note 11 - Grant Revenue	3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Government Grants and Contracts [Text Block]	*11.* Grant Revenue We receive payments from government entities under grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three-month periods ended March 31, 2022 and 2021, we recorded $81,526 and $110,417, respectively, of revenue associated with these grants.

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

No definition available.

Name:	govx_GovernmentGrantsandContractsTextBlock
Namespace Prefix:	govx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration